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nd who have hepatitis C virus (HCV) infection with advanced
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eir outcomes a year following treatment, in terms of deaths,
ncers and other complications of advanced liver disease. We
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en in advanced liver disease.troduction
ll-oral, interferon (IFN)-free direct-acting antiviral (DAA) ther-
y for chronic hepatitis C virus (HCV) infection has allowed suc-
ssful treatment of patients with advanced liver disease.
orldwide, large numbers of HCV-infected patients with decom-
nsated cirrhosis have received antiviral therapy and although
stained virological response (SVR) rates are slightly reduced
mpared to patients with compensated disease, over 80% of
eated patients still achieve viral clearance. Early analysis of
tients who responded to therapy showed associated improve-
ents in MELD and Child-Pugh scores [1–4], although some con-
rns have been expressed that the rate of malignancy may not
ange or may, paradoxically, increase [5,6]. Previous studies of
N-based therapies have demonstrated that HCV clearance
proves liver fibrosis, even in cirrhosis [7]. Moreover, patients
ho achieved SVR had reduced mortality, complications of cir-
osis and hepatocellular carcinoma compared to untreated
tients or those who failed to achieve SVR [8–10]. However,
6 vol. xxx j xxx–xxxirect-acting antiviral therapy for patients with chronic hepatitis C and
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80 such studies involved patients with relatively ‘early’ cirrhosis and
81 it remains unclear whether these long term benefits will be seen
82 in patients treated for more advanced disease. Although there is
83 little data on long term outcomes, international guidelines rec-
84 ommend that patients with decompensated cirrhosis should be
85 urgently treated with IFN-free DAA therapy, regardless of eligibil-
86 ity for liver transplantation [11,12].
87 Chronic HCV infection is the main indication for liver trans-
88 plantation in the Western world, and universally recurs causing
89 accelerated disease progression in the liver graft. Given the short-
90 age of donor organs and costs of liver transplantation, DAA treat-
91 ment may reduce the need for transplantation in patients with
92 advanced cirrhosis and allow alternative uses for scarce organs.
93 Pooled analysis of over 800 patients with decompensated cirrho-
94 sis showed that 60% of patients had an improvement in MELD
95 score from baseline following therapy, but 23% deteriorated, at
96 post-treatment weeks 4 to 12 [13]. The magnitude of improve-
97 ment varied with a median of 2 MELD points. It is unclear
98 whether this early change is clinically meaningful. Perhaps more
99 importantly, minor reductions in MELD may adversely affect
100 access to liver transplantation, if a patient no longer meets trans-
101 plant criteria but is insufficiently improved with a reduced qual-
102 ity of life (so called ‘MELD purgatory’). In such cases, therapy may
103 not be beneficial.
104 We recently published data on the virological and clinical out-
105 comes of patients with decompensated cirrhosis treated on the
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142The study conforms to the ethical guidelines of the 1975 Declaration of Hel-
143sinki as reflected in a priori approval by the institution’s human research commit-
144tee. Ethics approval for HCVRUK was given by the national research ethics service
145(NRES) committee East Midlands – Derby 1 (Research Ethics Committee reference
14611/EM/0314) and informed consent was obtained from each patient included in
147the study. Patients in the EAP who declined data collection (N = 13) were treated
148but were excluded from this analysis.
149Outcome measures
150Data on virological response and clinical outcomes at 12 weeks post-treatment
151on consenting patients treated in the EAP was previously published [14]. Here
152we focus on the clinical outcomes in patients with decompensated cirrhosis fol-
153lowed for up to a year post completion of therapy (total follow-up 15 months
154since start of therapy). Data was collected for the period post-treatment week
15512 to month 12 (month 6 to 15), via standardised electronic forms. Sites were
156individually re-contacted by the central study team with any missing or invalid
157responses, to ensure completeness and accuracy of collected data. This data
158was combined with earlier data from treatment start to month 6.
159Viral loads at 24 weeks post-treatment end or later were collected. We
160assessed the proportion of patients who achieved SVR after 24 weeks (SVR24),
161and those with late relapse after initial undetectable viral load at post-treatment
162week 12. All who relapsed were offered retreatment with 24 weeks therapy.
163The following primary clinical endpoints were collected: deaths, liver trans-
164plantations and hepatocellular carcinoma at 15 months (3 months on treatment,
16512 months post-treatment). Endpoints were calculated as 15 months from treat-
166ment start date, to account for premature treatment discontinuations.
167For patients who achieved SVR24, the following secondary endpoints were
168measured: serious adverse events (decompensation, sepsis, hospitalisation for
169any cause) between month 6 and 15, MELD scores at 15 months (for non-
170transplanted patients only). For patients who did not attend clinic at month 15,
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202patients (81.0%), including 4 patients originally classified as
Research Article
JHEPAT 6166 No. of Pages 8
11 July 2016English Expanded Access Programme (EAP) with 12 weeks o
sofosbuvir and a NS5A inhibitor with or without ribavirin [14
Consistent with other studies, the majority of patients success
fully achieved viral clearance associated with MELD improve
ments by post-treatment week 12. To assess the impact o
antiviral therapy in patients with decompensated cirrhosis, th
study compared treated patients to a retrospective cohort o
patients with decompensation who were untreated for 6 month
prior to the availability of DAAs. Treated patients had fewe
decompensations, reduced deterioration in MELD, and overa
adverse events, although there were no significant difference
in rates of death, liver transplantation or hepatocellular carc
noma [14]. To address the longer term benefits of successfu
HCV clearance, here we report the outcomes in the same patien
cohort followed-up for one year after completion of therapy.
Patients and methods
Patients who received DAA therapy through the English EAP were enrolled int
the HCV Research UK (HCVRUK) registry for prospective data collection. Patien
who started treatment between 1 April and 11 November 2014 were studie
Details of the EAP treatment and patient selection criteria were previously pub
lished [14]. In brief, treatment consisted of 12 weeks of sofosbuvir with ledipasv
or daclatasvir, with or without ribavirin. Treatment choice was according to loc
multidisciplinary meeting decisions by experienced clinicians. Eligible patien
included those with past or current decompensated cirrhosis (with ascites, var
ceal bleed or encephalopathy), Child-Pugh score B7 or above, extrahepatic HC
manifestations or exceptional circumstances which were determined by pan
review. Presence of hepatocellular carcinoma was not an indication for treatmen
in the EAP unless one of the above criteria was also met.
An untreated cohort of patients with decompensated HCV cirrhosis wer
studied for 6 months to compare early outcomes with patients who underwen
treatment on the EAP. They were not studied beyond 6 months of follow-up a
data was retrospectively collected. Untreated patients were registered in HCVRU
either at least 6 months prior to the national start date of the EAP (1 April 2014
or 6 months before initiation of treatment for those patients who subsequent
received DAAs. Further details on this comparator cohort have been describe
[14].Please cite this article in press as: Cheung MCM et al. Outcomes after success
decompensated cirrhosis. J Hepatol (2016), http://dx.doi.org/10.1016/j.jhep
2 Journal of Hepatology 2laboratory data from visits within 1 month of the timepoint were include
Patients who did not achieve SVR24 were not included. SVR24 was defined a
undetectable HCV RNA (measured at local laboratories with a lower limit of quan
tification of <30 IU/ml) at 24 weeks post-treatment. Where there was no resu
available at post-treatment week 24 but subsequent viral load was detectable,
was assumed that the patient had not achieved SVR24. MELD scores were calcu
lated using results provided by local accredited laboratories. Serious adverse even
was defined as life-threatening, requiring hospitalisation or prolonged existin
hospitalisation, resulting in persistent or significant disability, incapacity or deat
Statistical analysis was performed using Graphpad Prism 5. The following sta
tistical tests were performed: chi-squared test (for comparison of proportions),
test (for comparison of means) and log rank test (for comparison of survival).
Results
Patient population
A total of 480 patients received antiviral therapy through the EA
between the start of the programme on 1 April 2014 to 1
November 2014 – 467 (97.3%) patients consented to provide dat
to the HCVRUK registry and 406 (87%) patients had decompen
sated cirrhosis and/or Child-Pugh score PB7, without previou
liver transplantation, at treatment start. Sixty-one (13%) patient
were treated for extrahepatic HCV disease or aggressive HC
recurrence in liver grafts.
Table 1 shows the demographics and baseline liver disease o
patients with decompensation. The majority (295/406, 72.7%
were Child-Pugh B; 41 patients (10.1%) were Child-Pugh C. Th
remaining 70 patients (17.2%) had Child-Pugh A disease at base
line but a past history of liver decompensation. Most patients ha
significant portal hypertension represented by a median platele
count of 75  109/L.
Virological outcomes
SVR after 12 weeks (SVR12) was achieved in 329 out of 40ful direct-acting antiviral therapy for patients with chronic hepatitis C and
.2016.06.019
016 vol. xxx j xxx–xxx
203 non-SVR12 because no virology result was available, but who on
204 further follow-up, were shown to be HCV RNA negative. Four
205 patients relapsed after having a HCV RNA negative result at
206 post-treatment week 12 and a further 8 died in the follow-up
207 period after achieving SVR12. Therefore 317 (78.1%) patients
208 achieved SVR24. Of note there were no late relapses after post-
209 treatment week 12 amongst patients without baseline decom-
210 pensated cirrhosis.
211 Amongst the 89 patients who did not achieve SVR24, 53 had
212 virological failure (49 known before post-treatment week 12
213 and 4 late relapsers), 14 patients died before reaching post-
214 treatment week 12, and another 12 between post-treatment
215 12–24 weeks. Ten patients had no available viral results at
216 post-treatment week 24 although clinical outcomes data was still
217 provided. See Supplementary Table 1 for SVR24 according to
218 genotype and treatment regimen.
219 Of the 53 patients with virological failure, 21 had viral relapse
220 by post-treatment week 4, 24 patients by post-treatment week
221 12, and 4 relapsed after post-treatment week 12. Three patients
222 did not clear virus by the end of therapy and one patient without
223 a known virological result at post-treatment week 12 subse-
224 quently had documented relapse.
225 Forty-five of the patients with viral relapse were offered
226 retreatment with a 24 week course of the same drug regime
227 (switching NS5A inhibitor was not supported by the funders of
228 the EAP), the outcomes of which will be reported separately.
229 Eight patients declined retreatment.
230 Outcomes after 15 months in patients with decompensated cirrhosis
231 Mortality
232 In
233 de
234 SV
235 w
236Although virological failure was predominantly seen in genotype
2373 infected patients, the proportion who died did not differ
238between genotypes – there were 9 deaths amongst 24 genotype
2391 infected patients without SVR24, compared to 21 deaths
240amongst 60 genotype 3 infected patients without SVR24 (37.5%
241vs. 35.0%, p = 0.83). Fig. 1 shows the survival rates over the study
242period.
243Development of liver cancer
244At treatment baseline, 29 of 406 total patients had a history of
245HCC (median days between diagnosis and DAA start was
246287 days). Eighteen of these patients achieved SVR24 (Table 1).
247Two patients with pre-existing liver cancer history developed a
248new HCC (at 20 and 26 weeks from treatment start), both
249achieved SVR24. There were no recurrent HCCs amongst patients
250with previous cancer who did not achieve SVR24.
251Amongst 317 patients who achieved SVR24, 17 (5.4%) devel-
252oped a liver cancer (Table 2) over the follow-up period of
25315 months (15 de novo and 2 recurrent). Five of the 17 (29.4%)
254new liver cancers developed in patients who achieved SVR24
255occurred early, within 3 months of commencing treatment. There
256was a reduction (of borderline significance) in new cancer rates
257over 15 months between patients with and without SVR24
258(17/317, 5.4% vs. 10/89, 11.2%, p = 0.049) in patients with decom-
259pensated cirrhosis (hazard ratio 0.33, 95% CI 0.13–0.87) (see
260Fig. 2). This compares with 11/261 (4.2%) in untreated patients
261over 6 months.
262Other outcomes
263Ta
26415
265(1
266se
267m
Table 1. Baseline characteristics of patients according to treatment outcomes. Virological failure included all patients with a detectable viral load at post-treatment
week 24 or before, including re-treated patients. Non-SVR24 included in addition patients who died before post-treatment week 24 or without available viral load. Serious
adverse events included all deaths, transplants, HCCs, decompensations, sepsis and hospitalisation to month 15.
Baseline characteristic All decompensated SVR24 Non-SVR24 Virological failure SVR24 - serious 
adverse events 
SVR24 - no serious 
adverse events
All   N (%) 406 317 (78.1%) 89 (21.9) 53 (13.1) 135 (42.6%) 182 (57.4%)
SOF/LDV 18 (4.4) 12 (3.8) 6 (6.7) 4 (7.5) 7 (5.2%) 5 (2.7%)
SOF/LDV/RBV 228 (56.2) 187 (59.0) 41 (46.1) 30 (56.6) 78 (57.8%) 109 (59.9)
SOF/DCV 11 (2.7) 7 (2.2) 4 (4.5) 1 (1.9) 5 (3.7%) 2 (1.1%)
SOF/DCV/RBV 149 (36.7) 111 (35.0) 38 (42.7) 18 (34.0) 45 (33.3%) 66 (36.3%)
Genotype 1 198 (48.8) 174 (54.9) 24 (27.0) 11 (20.8) 75 (55.6%) 99 (54.4%)
Genotype 3 171 (42.1) 111 (35.0) 60 (67.4) 39 (73.6) 45 (33.3%) 66 (36.3%)
Other genotypes 37 (9.1) 32 (10.1) 5 (5.6) 3 (5.7) 15 (11.1%) 17 (9.3%)
Age (years) median, range 54, 28-79 54, 28-79 52, 30-74 52, 33-72 54, 33-76 55, 28-79
Bilirubin (μmol/L) median, range 29, 4-433 28, 4-311 34, 7-433 33, 7-148 30, 4-311 26, 6-90
Albumin (g/L) median, range 31, 17-55 31, 17-49 29, 21-55 30, 21-40 31, 17-45 32, 17-49
Platelets (x109/L) median, range 75, 3-321 75, 3-321 76, 20-277 76, 20-277 74, 20-237 76, 3-321
MELD median, range 12, 7-32 11, 7-32 13, 7, -25 12, 8-23 12, 7-32 11, 7-21
Child Pugh B 295 (72.7) 225 (71.0) 70 (78.7) 42 (79.2) 88 (65.3%) 137 (75.3%)
Child Pugh C 41 (10.1) 29 (9.1) 12 (13.5) 5 (9.4) 24 (17.8%) 5 (2.7%)
Baseline HCC 29 (7.1) 18 (5.7) 11 (12.4) 9 (17.0) 13 (9.6%) 5 (2.7%)
Since the earlier publication [4], 3 additional patients were confirmed as transplanted prior to DAA therapy, including one registered for therapy pre-transplant, grafted
then initiated treatment. These patients were re-defined as post-transplant at treatment baseline, therefore 406 instead of 409 patients were included in this study.
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aths over 15 months (9.9%) – 9 patients died who achieved
R24 (2.8%), which was not statistically different to patients
ith known virological failure (3/53, 5.7%, p = 0.28) (Table 2).lease cite this article in press as: Cheung MCM et al. Outcomes after successful d
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Journal of Hepatology 2016ble 2 shows the outcomes for patients followed-up for
months. Amongst the 317 patients who achieved SVR24, 39
2.3%) received a liver transplant. Forty-six patients experienced
rious decompensation between months 0–6 (14.5%) which was
arkedly reduced in months 6–15 (16/317, 5.0%) (p = 0.00006).irect-acting antiviral therapy for patients with chronic hepatitis C and
.06.019
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268
269
270
ants (O o
ated p d
only.
All treated
nth 0-
 (3.4%
 (4.2%
 (7.1%
 (17.7%
nth 0-
 (15.7%
6.7%)
2.2%)*
 (29.2%
s post- a
ogical
Research Article
JHEPAT 6166 No. of Pages 8
11 July 2016Table 2. Deaths, hepatocellular carcinomas (HCC), orthotoptic liver transpl
treatment outcomes, compared to patients untreated for HCV (data for untre
as non-SVR24. Decompensation events were recorded for patients with SVR24
Adverse event Untreated
N = 261
Month 0-6 Mo
Died 13 (5.0%) 14
HCC 11 (4.2%) ┼ 17
OLT 10 (3.8%) 29
Decompensation 73 (28.0) 72
Adverse event SVR24
N = 317
Month 0-6 Month 6-15 Overall Mo
Died 0 (0.0%) 9 (2.8%) 9 (2.8%) 14
HCC 11 (3.5%) 6 (1.9%) 17 (5.4%) 6 (
OLT 27 (8.5%) 12 (3.8%) 39 (12.3%) 2 (
Decompensation 46 (14.5%) 16 (5.0%) 52 (16.4%) 26
⁄Denotes two patients who did not have known virological outcomes at 24 week
new liver cancer.
⁄⁄⁄Denotes a patient transplanted by month 6 who did not have a known virol
ƗFigure updated from earlier publication.
0 3 6 9 12 15
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Month  0 3 6 9 12 15 
Untreated 261 254 248 - - - 
Treated  406 401 392 380 375 366 
100
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l %
A
BSupplementary Table 2 shows the details of these events with
incidences of decompensations, sepsis and all-cause hospitalisa-
tions which were graded as serious adverse events.
0 3 6 9 12 15
90
SVR24 (n = 317)
Virological failure (n = 53)
Months
S
ur
Number of patients at risk
Month  0 3 6 9 12 15 
SVR24 317 317 317 317 313 308 
Virological 
failure 
53 53 53 53 53 50 
Fig. 1. Survival of patients over 15 months. (A) Survival in patients treated and
untreated (log rank p = 0.32). (B) Survival in treated patients with SVR24 and
virological failure (log rank p = 0.38). Note by definition no deaths occurred before
month 9 (post-treatment week 24) in both groups.
Please cite this article in press as: Cheung MCM et al. Outcomes after success
decompensated cirrhosis. J Hepatol (2016), http://dx.doi.org/10.1016/j.jhep
4 Journal of Hepatology 2LT) and decompensations over 15 months for all treated patients according t
atients derived from [4]). Note all deaths up to post-treatment week 24 were define271t
272r,
273e
274s
)
)
k
4For patients who achieved SVR24, 135 (42.6%) experienced a
least one serious adverse event (death, transplant, liver cance
decompensation, sepsis or hospitalisation), therefore th
transplant-free, adverse event free survival over 15 months wa
N = 406
6 Month 6-15 Overall
) 26 (6.4%) 40 (9.9%)
) 10 (2.5%) 27 (6.7%)
) 17 (4.2%) 46 (11.3%)
) 30 (7.4%) 87 (21.4%)
Non-SVR24
N = 89
Virological failure
N = 53
6 Month 6-15 Overall Month 0-6 Month 6-15 Overall
) 17 (19.1%) 31 (34.8%) 0 (0%) 3 (5.7%)* 3 (5.7%)
4 (4.5%)** 10 (11.2%) 3 (5.7%) 3 (5.7%) 6 (11.3%)
** 5 (5.6%) 7 (7.9%) 1 (1.9%) 5 (9.4%) 6 (11.3%)
) - - - - -
treatment but had reported deaths, one of the two patients (marked by ⁄⁄) also had
outcome at 24 weeks post-treatment.
A
B
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Treated 406 398 389 383 381 379 
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00320330360331371342RVS
97080838689842RVS-noN
Fig. 2. Development of new hepatocellular carcinoma over 15 months. (A
New hepatocellular carcinoma in untreated and treated patients (log ran
p = 0.98). (B) New hepatocellular carcinoma in patients with and without SVR2
(log rank p = 0.02).27557.4%. The group with adverse events contained a significantly
ful direct-acting antiviral therapy for patients with chronic hepatitis C and
.2016.06.019
016 vol. xxx j xxx–xxx
276 higher proportion of patients with Child-Pugh C disease at base-
277 line – 24/135 (17.8%) for patients with adverse events and 5/182
278 (2.7%) for patients without adverse events (p <0.0005) (see
279 Table 1). Fig. 3 shows that adverse events were most frequent
280 during the treatment period, and decreased over time.
281 Earlier we published on the baseline characteristics of the
282 untreated and treated patients, showing that the two cohorts
283 were similar apart from a higher proportion of patients using
284 alcohol (of any amount) at baseline amongst untreated patients
285 [14]. Supplementary Table 3 illustrates that after excluding active
286 alcohol users, adverse outcomes remained less frequent in trea-
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11 July 2016d compared to untreated patients. Amongst untreated patients
ho subsequently received DAAs when they became available,
d were studied as the treated cohort at least six months later,
ere were numerically but not statistically significantly lower
cidences of liver cancers and decompensations following
eatment.
We previously proposed a model using baseline age and albu-
in to predict adverse outcomes at 6 months. Table 3 shows the
oportion of patients without adverse outcomes at month 15
sed on age and serum albumin at treatment start, however
ese baseline factors did not discriminate the likelihood of
veloping adverse events or not. We did not include MELD score
ange into the model due to the limited number of available
mparative scores.
ELD scores for patients with decompensated cirrhosis who
hieved SVR24
e mean MELD score change from baseline at month 6 was
0.83 ± 0.14 (improvement) and +0.51 ±0.4 at month 15 (deteri-
ation) (p <0.0001) based on 282 patients with available com-
rative scores at month 6 and 74 patients at month 15.
pplementary Fig. 1 shows the waterfall plots for MELD score
anges between baseline and month 6 and month 15 for non-
ansplanted patients who achieved SVR24. MELD improvement
as observed in patients with higher baseline score (see Supple-
entary Table 4) but even in for those with baseline MELD >15
e margin of improvement was smaller at 15 months than at
months. Supplementary Table 5 shows that based on the small
mber of available results, there were no patients with baseline
ELD <9 who worsened to above 15; for the majority group with
seline MELD 10–14 there were similar proportions who
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g. 3. Combined adverse event rate (death, liver transplant, HCC, decom-
nsation, sepsis, all-cause hospitalisation) per person over time, for patients
ith SVR24 (n = 307). Error bars represent 95% confidence intervals.lease cite this article in press as: Cheung MCM et al. Outcomes after successful d
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Journal of Hepatology 2016proved or deteriorated but 48.8% had no significant change
MELD at month 15.
iscussion
e availability of highly effective all-oral antiviral regimens for
tients with chronic HCV infection has transformed the treat-
ent options for infected patients and most patients can now
hieve viral clearance. For patients with advanced liver disease
is unclear whether viral eradication is beneficial and there
e some reports suggesting that it may be harmful. Indeed, the
finition of benefit following viral clearance, whether it is
tient survival, access to transplantation or avoidance of com-y in patients with end-stage liver disease we examined med-
m term outcomes in the English Expanded Access
ogramme. This involved a well-studied, prospectively enrolled
hort of patients managed by experienced clinicians in a limited
mber of centres. Data collection was to clinical trial standards
though external audit was not performed. Although observa-
nal studies in non-clinical trial conditions may be confounded
subject or clinician non-compliance, the patient cohort in this
udy all had advanced liver disease requiring regular medical
tervention and the treating centres were all experienced in data
ndling techniques and were provided with support and
sources from the central administration. We therefore believe
at our dataset is likely to be accurate and complete with min-
al errors from reporting or attendance failure.
One limitation of the study is the choice of control subjects –
treated patients with decompensated cirrhosis were selected
sed on the same criteria as treated patients, from the same reg-
try, but were not otherwise matched. Treated and untreated
tients had similar demographics and baseline liver disease,
art from the proportion of active alcohol users which was
gher in untreated patients. Excluding patients using any
ount of alcohol at baseline, who had additional risks for dis-d total adverse events compared to untreated [14]. Although
tients during treatment were followed-up more closely, all
tients were regularly reviewed due to their advanced liver dis-
se. The study evaluated serious adverse events which were
tively monitored for (all patients were offered HCC surveil-biased by differences in the frequency of routine follow-up.
e majority of the untreated cohort subsequently received DAAs
hen they became available, and about half were included in the
eated cohort. Thus the same patients were studied at least six
onths later, during their treatment period, and there was no
crease in the incidences of decompensations and liver cancers.
Recent studies highlighting the possibility of an increased
cidence or recurrence of liver malignancy in patients with
compensated cirrhosis who achieve viral clearance with DAA
gimens has led some to question the value of treating such
tients [5,6]. In the English EAP, patients with liver cancer were
t indicated for treatment unless they had decompensated cir-
osis. We did not see any evidence of an increase in liver cancer
ring therapy and the following 12 months. Nearly a third of theirect-acting antiviral therapy for patients with chronic hepatitis C and
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11 July 2016newly detected liver cancers occurred in the first 3 months o
therapy, suggesting this was growth from cancers which wer
radiologically undetectable at treatment baseline, rather tha
de novo development. There is potential bias that in a cohort o
patients with decompensated cirrhosis, development or detec
tion of liver cancer is masked by death driven by advanced live
disease. We observed a reduction in cancer rates in patients wit
Table 3. Proportion of patients without adverse events (death, transplanta
tion, liver cancer, decompensation, sepsis or hospitalisations) according t
baseline characteristics. Total 182 patients out of 317 who achieved SVR24.
N No adverse events (n)
Age <65 Albumin ≥35 74 47 63.5%
Age <65 Albumin <35 212 120 56.6%
Age ≥65 Albumin <35 21 10 47.6%
Age ≥65 Albumin ≥35 10 5 50.0%SVR compared to virological failure, but the relatively short dura-
tion of follow-up and the low incidence of such events prevent a
clear conclusion at this stage.
In the IFN era, antiviral therapy in patients with cirrhosis was
associated with reduced hepatocellular carcinoma [9]. Large
cohorts such as HALT-C have demonstrated that reduced cancer
development may be an effect of IFN, which has anti-tumour
properties, rather than viral clearance alone, although this was
only observed after four years from treatment [15]. The magni-
tude of the impact of clearing HCV with DAAs on liver cancers
may require data pooling from studies with longer follow-up,
and may differ depending on the degree of cirrhosis or whether
there is previous history of HCC. The reduction in liver cancer
rates from 4% in 261 untreated patients over 6 months to 1.9%
over 9 months after achieving viral clearance in 317 successfully
treated patients reassures us that induction of liver cancer in our
patients did not occur.
The long term benefits of viral eradication on liver function
and the complications of portal hypertension remain unclear.
However, in our cohort there was a marked reduction in liver
related serious adverse events in those patients who cleared
virus, with decreasing adverse events rates over time. We specu-
late that patients will continue to benefit long term although fur-
ther data will be required to confirm this.
The value of antiviral therapy in patients with decompensated
cirrhosis will remain a subject for debate until very large cohorts
have been evaluated for extended periods of time. Our data on
12 months follow-up after treatment of a large English cohort
indicates that there are benefits for many patients, although in
patients with Child-Pugh C disease viral clearance may have the
least impact on liver complications. In our view it is important
that liver transplantation remains available for patients with very
advanced disease who achieve viral clearance, as such patients
may not improve to a level commensurate with a high quality
of life.
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